Fig. 3

Efficacy of switching to mepolizumab from omalizumab by prior treatment regimen and omalizumab treatment duration. *Pre-treatment refers to the 12 months prior to screening; †32-week study period refers to the time between first dose of mepolizumab and study conclusion, regardless of treatment discontinuation. Rate ratio reflecting annualised clinically significant exacerbation rate during 32-week study period compared with rate during pre-treatment period. MCID for ACQ-5 and SGRQ is 0.5 points and 4 points, respectively; error bars represent SE. ACQ Asthma Control Questionnaire, CI confidence interval, FEV₁ forced expiratory volume in 1s, LS least squares, MCID minimum clinically important difference, RR rate ratio, SE standard error, SGRQ St. George's Respiratory Questionnaire